HK1116806A1 - Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins - Google Patents
Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophinsInfo
- Publication number
- HK1116806A1 HK1116806A1 HK08107507.3A HK08107507A HK1116806A1 HK 1116806 A1 HK1116806 A1 HK 1116806A1 HK 08107507 A HK08107507 A HK 08107507A HK 1116806 A1 HK1116806 A1 HK 1116806A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- post
- antibody fragments
- translationally modified
- scfv binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06291195A EP1882697B1 (de) | 2006-07-24 | 2006-07-24 | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1116806A1 true HK1116806A1 (en) | 2009-01-02 |
Family
ID=37075006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08107507.3A HK1116806A1 (en) | 2006-07-24 | 2008-07-08 | Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100055109A1 (de) |
EP (2) | EP1882697B1 (de) |
JP (1) | JP5528803B2 (de) |
AR (1) | AR062038A1 (de) |
AT (1) | ATE465179T1 (de) |
BR (1) | BRPI0714545A2 (de) |
CA (1) | CA2657563A1 (de) |
DE (1) | DE602006013809D1 (de) |
HK (1) | HK1116806A1 (de) |
UY (1) | UY30501A1 (de) |
WO (1) | WO2008012049A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602006013809D1 (de) * | 2006-07-24 | 2010-06-02 | Facultad De Medicina Universid | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
WO2012033916A1 (en) * | 2010-09-08 | 2012-03-15 | Southern Illinois University Edwardsville | Method for treating chronic pain |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
AU2011336470B8 (en) | 2010-12-01 | 2017-09-14 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
US20180236031A1 (en) * | 2017-02-10 | 2018-08-23 | Vivibaba, Inc | Compositions and methods for recombinant nerve growth factor |
CA3095125A1 (en) * | 2018-03-27 | 2019-10-03 | Factor Bioscience Inc. | Nucleic acid-based therapeutics |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
US6068040A (en) | 1998-07-24 | 2000-05-30 | Alpine Overhead Doors, Inc. | Slat edge retainer for overhead rolling doors |
EP1500399A1 (de) * | 2003-07-24 | 2005-01-26 | Institut Pasteur | Aktive und passive Immunisierung gegen pro-apoptotischen Neurotrophinen zur Behandlung oder Vorbeugung von neurologischen Krankheiten |
DE602006013809D1 (de) * | 2006-07-24 | 2010-06-02 | Facultad De Medicina Universid | Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden |
-
2006
- 2006-07-24 DE DE602006013809T patent/DE602006013809D1/de active Active
- 2006-07-24 AT AT06291195T patent/ATE465179T1/de not_active IP Right Cessation
- 2006-07-24 EP EP06291195A patent/EP1882697B1/de not_active Not-in-force
-
2007
- 2007-07-23 CA CA002657563A patent/CA2657563A1/en not_active Abandoned
- 2007-07-23 JP JP2009521157A patent/JP5528803B2/ja not_active Expired - Fee Related
- 2007-07-23 BR BRPI0714545-4A patent/BRPI0714545A2/pt not_active IP Right Cessation
- 2007-07-23 EP EP07786268A patent/EP2046823B1/de not_active Not-in-force
- 2007-07-23 US US12/374,485 patent/US20100055109A1/en not_active Abandoned
- 2007-07-23 WO PCT/EP2007/006528 patent/WO2008012049A1/en active Application Filing
- 2007-07-24 AR ARP070103275A patent/AR062038A1/es unknown
- 2007-07-24 UY UY30501A patent/UY30501A1/es not_active Application Discontinuation
-
2008
- 2008-07-08 HK HK08107507.3A patent/HK1116806A1/xx not_active IP Right Cessation
-
2013
- 2013-09-26 US US14/037,973 patent/US9328163B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
UY30501A1 (es) | 2009-04-30 |
US9328163B2 (en) | 2016-05-03 |
JP2010501475A (ja) | 2010-01-21 |
ATE465179T1 (de) | 2010-05-15 |
WO2008012049A1 (en) | 2008-01-31 |
CA2657563A1 (en) | 2008-01-31 |
US20100055109A1 (en) | 2010-03-04 |
AR062038A1 (es) | 2008-08-10 |
DE602006013809D1 (de) | 2010-06-02 |
EP2046823A1 (de) | 2009-04-15 |
US20140178384A1 (en) | 2014-06-26 |
BRPI0714545A2 (pt) | 2013-05-14 |
EP1882697A1 (de) | 2008-01-30 |
EP1882697B1 (de) | 2010-04-21 |
EP2046823B1 (de) | 2012-11-21 |
JP5528803B2 (ja) | 2014-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1116806A1 (en) | Antibodies, antibody fragments and scfv binding to post-translationally modified neurotrophins | |
HRP20190312T1 (hr) | Vežući proteini, uključujući protutijela, derivate protutijela i fragmente protutijela, koji se specifično vežu na cd154 i njihova upotreba | |
ZA201003496B (en) | Monoclonal antibody capable of binding to anexelekto,and use thereof | |
IL240245A (en) | 5t4 antibodies and their uses | |
IL198592A0 (en) | Tes7 and antibodies that bind thereto | |
HK1194395A1 (zh) | 抗體及其製備和使用方法 | |
ZA200809662B (en) | Modified humanised anti-interleukin-18 antibodies | |
EP2091975A4 (de) | Antikörper gegen die egfr-familie, bispezifische antikörper gegen die egfr-familie und verfahren zu ihrer verwendung | |
EP2322562A4 (de) | Monoklonaler antikörper und immunassay damit | |
ZA200905874B (en) | Monoclonal human tumor-specific antibody | |
IL236237A (en) | Tmem154 antibodies and their segments and uses | |
IL220622A0 (en) | Monoclonal antibodies against activated and unactivated protein c | |
EP2281004A4 (de) | Prostataspezifische membranantigenantikörper und antigenbindende fragmente | |
EP2303924A4 (de) | Lm-antikörper, funktionelle fragmente, lm-1-zielantigen und verfahren zu ihrer herstellung und verwendung | |
HK1158977A1 (zh) | 抗膜鐵轉運蛋白 單克隆抗體及其用途 | |
IL208188A0 (en) | Compositions comprising antibodies or antibody fragments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150724 |